PALO ALTO, Calif.--Incyte Pharmaceuticals warned investors last week that it will report a larger than expected third-quarter loss. Roy Whitfield, Incyte's CEO, attributed the results to lengthy deal cycles and delays in finalizing two government contracts, but analysts and industry insiders speculated that increased competition in the genomic database market is leading to data commoditization and eroding prices.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.